US/UK/Canada

Share

Quotes

We are very excited to enter into this collaboration with a development partner with such broad experience and expertise in the field as well as direct market knowledge and legacy. Wider patient access to naloxone is one of the goals of many health authorities throughout the world and we believe KL-00514 can provide broad access and relative ease of use for a very competitive cost.
Dr. Scott Boyer, CEO, Klaria
Collaborating on the development of KL-00514, a product designed to specifically address opioid overdose, is another concrete step we are taking to address a serious public health issue crisis Canadians are facing. Prescription opioid medicines remain a safe and effective treatment option for patients who are appropriately selected and monitored; however, these medicines have risks. It is our goal to provide access to life-saving treatments that support the combined efforts of regulators and governments of all levels to make treatments for intentional or accidental overdose as broadly available as possible.
Dr. Craig Landau, President and CEO, Purdue Pharma (Canada)
Investing in drug development to bring value to patients has always been an integral part of Purdue Canada’s contributions to the healthcare system and to Canadian patients. In the case of KL-00514, subject to successful clinical development and subsequent approval by Health Canada, those who use diverted medications and suffer from accidental or intentional overdose may also benefit.
Dr. Craig Landau, President and CEO, Purdue Pharma (Canada)
The granting of the patent in Mexico completes the patent protection we have been seeking for all of North America. Mexico joins Canada and of course the US in the expanding list of areas in which our products will enjoy patent protection. In fact, the US patent will extend into 2029
Dr. Scott Boyer, CEO of Klaria Pharma Holding AB
”We have chosen to start with one of the most interesting projects in our portfolio – KL-00119. All of our projects have three important steps in their development and now KL-00119 have passed the first – to assure a functional formulation. The next critical milestone will be to perform the clinical trial and this is where both Recipharm and CTC will be extremely important collaborators”
Scott Boyer, CEO, Klaria Pharma Holding
”Both Recipharm and CTC have a huge amount of experience in their respective areas and we have complete faith in their ability to execute their parts of our project with high quality, to expected costs and to the agreed timelines”
Scott Boyer, CEO, Klaria Pharma Holding
The ambition is to create world-leading products in the area of acute pain management
Dr. Scott Boyer, CEO, Klaria
Beyond the pain management we also want to give the patient back a sense of control. For patients that are affected by recurrent and severe bouts of pain, the sense of control is often just as valuable as the actual pain management.
Dr. Scott Boyer, CEO, Klaria
By combining our unique drug delivery platform with proven drugs, we will be able to offer a medication the will allow patients never to have to use a nasal spray, swallow a tablet or to inject themselves. These are exactly the type of products patients, healthcare professionals and regulatory authorities are asking for
Dr. Scott Boyer, CEO, Klaria
Pick a time period -

Klaria receives 2,6 MSEK payment from Imbrium Therapeutics in the Epinephrine Alginate Film R&D Collaboration

Klaria Pharmaceuticals announced today that it has received additional funding from its partner Imbrium Therapeutics to fund additional research in the Epinephrine Alginate Film collaboration.  The partners are collaborating on the research and development of Epinephrine Alginate Film for the treatment of serious allergic reactions, so called Anaphylactic Shock.Klaria Pharmaceutical’s drug candidate Epinephrine Alginate Film is being developed as an alternative to injector-pens.  These injection pens are difficult to use and many patients fear using them. As a result, there is a risk that

Klaria Year-End Report

Klaria Year-End Report 1 January–31 December 2022 Q4 2022Summary of the Year-End Report Successful rights issue brought 59.2 MSEK to Klaria New collaboration agreement signed with PharmaMar fourth quarter of 2022 - Net sales amounted to 2.2 MSEK (0.0 MSEK) - Other income amounted to 0.2 MSEK (6.2 MSEK) - R&D costs for the period amounted to 8.6 MSEK (28.1 MSEK) - Profit after tax amounted to -12.9 MSEK (-24.8 MSEK) - Earnings per share for the quarter amounted to -0.22 SEK (-0.48 SEK) - Cash flow from operating activities amounted to -10.7 MSEK (-14.6 MSEK) - Cash

Outcome in Klaria’s rights issue

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO RUSSIA, BELARUS, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SWITZERLAND, SINGAPORE, SOUTH AFRICA, UNITED STATES OF AMERICA OR ANY OTHER JURISDICTION WHERE SUCH ACTION IS IN WHOLE OR IN PART FOR LEGAL RESTRICTIONS. THIS PRESS RELEASE DOES NOT CONSTITUTE AN OFFER TO ACQUIRE SECURITIES IN KLARIA. SEE THE "IMPORTANT INFORMATION" SECTION BELOW. Klaria Pharma Holding AB ("Klaria" or "the Company"), today announced the outcome of the rights issue with preferential rights for the shareholders (the “Rights

Klaria Pharma Holding AB: Klaria publishes prospectus relating to the rights issue and gives update regarding the level of undertaking of the rights issue

Klaria Pharma Holding AB (”Klaria” or the “Company") today announces that the prospectus relating to the Company's rights issue (the "Rights Issue") has been approved and registered by the Swedish Financial Supervisory Authority (the “SFSA”, sw. Finansinspektionen) (the "Prospectus"). The Company also announces that the Rights Issue of up to SEK 74.0 M before issuing costs has been secured up to 80 per cent by an increased top guarantee undertaking.Publication of the prospectus The prospectus that Klaria has prepared due to the upcoming rights issue has today been approved and registered

Bulletin from the extraordinary general meeting in Klaria Pharma Holding AB (publ)

At the extraordinary general meeting held in Klaria Pharma Holding AB (publ) today on 30 November 2022, it was resolved to approve the board of directors’ resolution on issuance of shares with preferential rights for the shareholders (in accordance with the proposal presented in the notice to attend the meeting kept available at the company’s website www.klaria.com).The extraordinary general meeting resolved to approve the board of directors’ resolution made on 14 November 2022 on issuance of shares with preferential rights for the shareholders. As announced on 14 November 2022, the terms

Klaria submits Marketing Authorization Application for Sumatriptan Alginate Film in Europe

UPPSALA — November 29, 2022 — Klaria Pharma AB (publ) (Nasdaq Stockholm: KLAR) today announces that the Company has submitted a Marketing Authorization Application (MAA) for Sumatriptan Alginate Film for the treatment of Migraine in the European Union.  Pending positive validation, Sumatriptan Alginate Film will be subject to a regulatory assessment according to the standard timeline, which would result in approval in Q1, 2024.“Sumatriptan Alginate Film addresses an important medical need in patients with migraine.  With the submission of the MAA, we have now successfully done everything we

Klaria Interim Report

Klaria Interim report Q3 2022 1 July- 30 September 2022Summary of the interm report Third quarter of 2022 - Net sales amounted to 0.0 MSEK (0.0 MSEK) - Other income amounted to 0.0 MSEK (0.0 MSEK) - R&D costs for the period amounted to 10.9 MSEK (12.5 MSEK) - Profit after tax amounted to -16.1 MSEK (-12.2 MSEK) - Earnings per share for the quarter amounted to -0.27 SEK (-0.24 SEK) - Cash flow from operating activities amounted to -3.6 MSEK (-13.7 MSEK) - Cash and cash equivalents on the balance sheet date amounted to 6.7 MSEK (25.9 MSEK) - Equity as of September

Klaria and PharmaMar initiate collaboration with a one-year study to develop a clinical development candidate of a PharmaMar compound formulated in Klaria’s Alginate Film technology

Klaria Pharma Holding AB (Nasdaq Stockholm: KLAR) announces that the company has signed an agreement with the Spanish biopharmaceutical company Pharma Mar (MSE:PHM), with the aim of performing a feasibility study for the purpose of developing an Alginate Film formulation of a PharmaMar compound. In the event of a positive outcome for this formulation development, the parties intend to negotiate a license agreement which will grant PharmaMar the global rights to the product.Klaria expanding collaboration based business model This collaboration with PharmaMar is the third research and

Klaria Interimreport 1 January–30 June 2022 Q2 2022

Klaria Interimreport 1 January–30 June 2022 Q2 2022Summary of the interim report Second quarter of 2022 - Net sales amounted to 0.0 MSEK (0.0 MSEK) - Other income amounted to 3.7 MSEK (0.0 MSEK) - R&D costs for the period amounted to 14.7 MSEK (11.5 MSEK) - Profit after tax amounted to -14.5 MSEK (15.9 MSEK) - Earnings per share for the quarter amounted to -0.24 SEK (0.31 SEK) - Cash flow from operating activities amounted to -15.7 MSEK (13.5 MSEK) - Cash and cash equivalents on the balance sheet date amounted to 7.3 MSEK (39.7 MSEK) - Equity as of June 30

Klaria Pharma to Present at BioStock Life Science Spring Summit 2022 on June 8th

UPPSALA, 3 June, 2022. Klaria Pharma AB (Nasdaq Stockholm: KLAR) announces today that the company‘s CEO, Jesper Wiklund, will participate at the BioStock Life Science Spring Summit 2022 on June 8[th] and present Klaria Pharma.  Klaria Pharma’s presentation will start at 14:00/2 pm CET. Follow the event online here: https://youtu.be/RmhNVEZSCww For additional information please contact: Investor Relations, Klaria Pharma ABTel: +46 (0)8 446 42 99, e-mail: investor.relations@klaria.com

Klaria Interim Report Q1 2022

Klaria Interim Report Q1 2022Summary of the Interim Report First quarter of 2022 - Net sales amounted to 0.0 MSEK (0.0 MSEK) - R&D costs for the period amounted to 17.1 MSEK (11.4 MSEK) - Profit after tax amounted to -20.3 MSEK (-16.7 MSEK) - Earnings per share for the quarter amounted to -0.37 SEK (0.32 SEK) - Cash flow from operating activities amounted to -19.8 MSEK (17.1 MSEK) - Cash and cash equivalents on the balance sheet date amounted to 23.0 MSEK (48.2 MSEK) - Equity as of March 31 amounted to 72.1 MSEK (126.3 MSEK) - Pursuant to the authorization granted

Klaria Pharmaceuticals enters into Agreement with FluiMed GmbH to develop Sirolimus Alginate Film for prevention of Organ Transplant Rejection

Uppsala, 30 March, 2020.  Sirolimus has an immunosuppressant  function and is used to prevent the rejection of organs in Solid Organ Transplantation (SOT) procedures.  However, both the efficacy and safety of Sirolimus varies greatly between individual patients.  This variability is due to how the treatment is metabolized.  An Alginate Film that delivers Sirolimus directly into the blood stream via the oral mucosa would not be subject to this variability.  The result would be a treatment that would make life-saving Solid Organ Transplant

Klaria Annual Report 2021

Summary of the year- Net sales amounted to 0.0 MSEK (0.0 MSEK) - Other operating income amounted to 37.5 MSEK (8.0 MSEK) - R&D costs amounted to 63.5 MSEK (48.4 MSEK) - Profit/loss after tax amounted to -53.5 MSEK (-51.4 MSEK) - Earnings per share amounted to -1.03 SEK (-1.19 SEK) - Cash flow from operations amounted to -24.8 MSEK (-35.3 MSEK) - Shareholder’s equity as of December 31, 2021 amounted to 69.4 MSEK (109.6 MSEK) - Cash and cash equivalents as of December 31, 2021 amounted to 25.5 MSEK (31.3 MSEK)

Resolution on allotment in directed share issue

UPPSALA, 17 March 2022.  As previously announced, the board of directors of Klaria Pharma Holding AB (“Klaria” or the “Company”) resolved on 11 March 2022, with support of the authorization from the annual general meeting held on 18 March 2021, to carry out a directed issue of new shares to approximately ten selected Swedish and international investors. All shares were subscribed for during the subscription period in accordance with the issue resolution, and the board of directors of Klaria has today resolved on allotment of in total 5,750,000 shares to the subscribers, in accordance with the

Klaria Pharma Holding AB (publ) issues notice to attend the annual general meeting

The shareholders in Klaria Pharma Holding AB (publ), reg. no. 556959-2917, are hereby given notice to attend the annual general meeting on 19 April 2022.Special arrangements due to the risk for spread of the virus COVID-19 (coronavirus) The board of directors has, in light of continued spread of the coronavirus and in accordance with the Swedish Act (2022:121) on temporary exceptions to facilitate the execution of general meetings in companies and other associations, decided that the annual general meeting shall be held without physical presence of shareholders, proxies and/or external

Klaria Pharma Holding AB (publ) issues notice to attend the annual general meeting

The shareholders in Klaria Pharma Holding AB (publ), reg. no. 556959-2917, are hereby given notice to attend the annual general meeting on 24 March 2022.Special arrangements due to the risk for spread of the virus COVID-19 (coronavirus) The board of directors has, in light of continued spread of the coronavirus and in accordance with the Swedish Act on temporary exceptions to facilitate the execution of general meetings in companies and other associations which is expected to enter into force on 1 March 2022, decided that the annual general meeting shall be held without physical presence

Patent for Klaria’s Sumatriptan Alginate Film Granted in Russia

Klaria’s patent for Sumatriptan Alginate Film has been granted in Russia.  This grant extends the global patent protection for Klaria’s most advanced development program.  The period of patent protected exclusivity in the Russian Federation will last until 2037.UPPSALA, 10 February, 2021. The granted Sumatriptan Alginate Film patent protects the combination of the active substance, Sumatriptan, with the Alginate Film.  The period of patent protected exclusivity in Russian will last until 2037.  This granting of the Sumatriptan Alginate Film patent is the third granting of this patent world-

Klaria Year-End Report Q4 2021

Klaria Year-End Report Q4 2021Summary of the Year-End Report Promising quarter with registration applications and preparations for additional clinical studies Fourth quarter of 2021 - Net sales amounted to 0.0 MSEK (0.0 MSEK) - Other income amounted to 6.2 MSEK (2.0 MSEK) - R&D costs for the period amounted to 28.1 MSEK (17.6 MSEK) - Profit after tax amounted to -39.1 MSEK (-17.0 MSEK) - Earnings per share for the quarter amounted to -0.75 SEK (-0.36 SEK) - Cash flow from operating activities amounted to -14.6 MSEK (-10.0 MSEK) - Cash and cash equivalents on the

Patent for Klaria’s Sumatriptan Alginate Film to be Granted in Mexico

Klaria has received notification that the patent for its Sumatriptan Alginate Film will be granted in Mexico.  This extends the geographic coverage of Klaria’s patent protection in the important North American market.  The period of patent protected exclusivity in Mexico will last until 2037.UPPSALA, 11 January, 2021. An important part of Klaria’s intellectual property strategy is to file combination patents.  These patents are specific for the combination of the active substance with the Alginate Film.  The granting of the Sumatriptan Alginate Film combination patent in Mexico is further

Bulletin from the extraordinary general meeting in Klaria Pharma Holding AB (publ)

At the extraordinary general meeting held in Klaria Pharma Holding AB (publ) today on 30 December 2021, it was resolved (all in accordance with the proposals presented in the notice to attend the meeting kept available at the company’s website www.klaria.com):· It was resolved to approve an addendum agreement with FFT Medical AB in order to finally settle the purchase price for Klaria’s acquisition of all shares in Uppsalagruppen Medical AB from FFT Medical AB during 2019. In light of Fredrik Hübinette, chairman of the board of Klaria, owning over 20 per cent of the shares in FFT Medical AB,

Klaria Pharma initiates clinical study with Naloxon Alginate Film

UPPSALA, 20 December, 2021. Klaria Pharma AB (Nasdaq Stockholm: KLAR) announces today that is has started a clinical trial with Naloxone Alginate Film and that the first group of subjects have received their first doses in the trial.  The data from this clinical trial will be used to submit an application for approval with both the EMA in Europe and the FDA in the United States.  With a more patient friendly formulation that is being specifically developed to meet the needs of patients and caregivers today, Naloxone Alginate Film has the potential to be superior to all Naloxone nasal sprays

Klaria Pharma Holding AB (publ) issues notice to attend extraordinary general meeting

The shareholders in Klaria Pharma Holding AB (publ), reg. no. 556959-2917, are hereby given notice to attend the extraordinary general meeting on 30 December 2021.Special arrangements due to the risk for spread of the virus COVID-19 (coronavirus) The board of directors has, in light of continued spread of the coronavirus and in accordance with the Swedish Act (2020:198) on temporary exceptions to facilitate the execution of general meetings in companies and other associations, decided that the extraordinary general meeting shall be held without physical presence of shareholders, proxies

Klaria Pharma receives approval to initiate clinical Phase 1 trial of Naloxone Alginate Film

UPPSALA, 2 December, 2021. Klaria Pharma AB (Nasdaq Stockholm: KLAR) announces today that is has received approval from the regulatory authorities in the United Kingdom (MHRA) to carry out a clinical Phase 1 study with Naloxone Alginate Film, a new treatment of opioid overdose. With a more patient friendly formulation that is being specifically developed to meet the needs of patients and caregivers today, Naloxone Alginate Film has the potential to be significantly superior to all Naloxone nasal sprays currently in use.Naloxone Alginate Film is addressing a market with significant unmet

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe